A Children’s Oncology Group pilot study for the treatment of very high risk acute lymphoblastic leukemia in children and adolescents - COGAALL0031

Children's Oncology Group (COG)0 个研究点目标入组 160 人开始时间: 2012年3月16日最近更新: 2012年4月3日

适应症

试验速览

暂无简介。

•1. Patients 1 to 20 years of age diagnosed with ALL who achieve remission after frontline induction therapy must have one of the features listed below:
•a. Ph+ ALL: presence of t(9;22)(q34;q11) determined by institutional cytogenetics or FISH; and/or presence of BCR-ABL fusion transcript identified by RT-PCR
•b. Hypodiploid with = 44 chromosomes
•2. Patients 1 to 20 years of age diagnosed with ALL who do not achieve remission after frontline induction therapy must have one of the features listed below:
•a. M3 (> 25% blasts) bone marrow status at the end of initial induction therapy
•b. M2 (5-25% blasts) bone marrow status at the end of initial induction therapy and M2 or M3 bone marrow status at end of consolidation therapy (CCG studies) or at the end of the extended induction phase (POG studies).
•3. Patients who are Ph+, hypodiploid with = 44 chromosomes, or M3 at the end of induction therapy must enroll on study within 42 days of initial diagnosis.
•4. Patients who are M2 at the end of induction and M2 or M3 at the end of consolidation therapy (CCG) or extended induction therapy (POG) must enroll within 14 days of their last day of frontline therapy
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

发起方

Children's Oncology Group (COG)